The Scientist Speaks – Homing in on New Anticancer Targets

Share this post on:


Cancers are diverse and adaptable. That is why a staggering 97% of cancer drugs in clinical trials fail to receive FDA approval. Researchers try to stay one step ahead of cancer by studying the mechanisms that lead to drug resistance, finding new drug targets, and developing novel therapies, such as immunotherapeutics. In this episode narrated by Niki Spahich, Sejal Davla from The Scientist’s Creative Services team spoke with Jason Sheltzer, an assistant professor in the Department of Genomics, Genetics, and Epigenomics and Yale Cancer Center at the Yale School of Medicine, about his work on drug resistance in cancer, chromosomal instability in cancer cells, and approaches to identify new treatment strategies.

Share this post on:

Leave a Reply

Your email address will not be published. Required fields are marked *